Anxiety & Depression — A Metabolic Reframe
New research is reframing anxiety and depression as metabolic conditions — not just neurochemical ones.
The dominant model of anxiety and depression — the serotonin/norepinephrine imbalance theory — has driven pharmaceutical treatment for decades. But it has significant limitations: roughly 30–40% of patients don't respond adequately to first-line antidepressants, and many who do respond experience incomplete remission with persistent cognitive and physical symptoms.
Emerging research — most prominently the work of Dr. Chris Palmer at Harvard, outlined in his book Brain Energy — is reframing anxiety and depression as metabolic and mitochondrial conditions. The brain consumes 20% of total body energy. When mitochondrial function declines — from chronic stress, poor sleep, inflammation, or aging — mood regulation is one of the first casualties.
Peptide therapy approaches this from a fundamentally different angle: rather than adjusting neurotransmitter levels, it targets the cellular energy infrastructure and neuroprotective mechanisms that make healthy mood regulation possible in the first place.
Dr. Chris Palmer's Brain Energy hypothesis proposes that mental illness is fundamentally a metabolic disorder — and that improving mitochondrial function is a more durable path to mood recovery than neurotransmitter manipulation alone. This framework directly supports the use of mitochondrial-targeted peptides like SS-31 and metabolic interventions like Selank and CAX in mood disorder protocols.
What's Driving Anxiety & Depression?
Four metabolic and neurological drivers — each addressable with targeted peptide interventions.
Reduced ATP production in neurons impairs the energy-intensive processes of neurotransmitter synthesis, synaptic signaling, and neuroplasticity. The brain simply cannot regulate mood effectively without adequate cellular energy — making mitochondrial support foundational to any mood protocol.
Chronic low-level inflammation crosses the blood-brain barrier, disrupting serotonin synthesis, impairing neuroplasticity, and activating the kynurenine pathway — which diverts tryptophan away from serotonin production toward neurotoxic metabolites. Neuroinflammation is now recognized as a primary driver of treatment-resistant depression.
Depression is associated with reduced BDNF (Brain-Derived Neurotrophic Factor) — the protein that supports neuron survival, growth, and the formation of new synaptic connections. Without adequate BDNF, the brain loses the structural flexibility needed for emotional regulation and recovery from stress.
Sleep is when the brain consolidates emotional memories, clears neurotoxic waste, and resets stress hormone levels. Disrupted deep sleep — which worsens with age and stress — amplifies both anxiety and depressive symptoms while impairing the overnight repair that mood regulation depends on.
Peptides for Anxiety & Depression
Five compounds addressing mood disorders from the metabolic and neuroprotective angle — with Selank and CAX as the anchors.
-
★ Anchor — Anxiety Selank (Selank) Selank is a neuroprotective peptide with particular efficacy for anxiety. Unlike benzodiazepines or SSRIs, it works through brain-specific neuroprotective signaling pathways rather than broad systemic sedation — delivering meaningful anxiety relief without dependency risk. Also supports BDNF expression and cognitive clarity. Available as nasal spray (most common) or subcutaneous injection. Effects on anxiety are typically noticeable within the first course.
-
★ Anchor — Depression & Mood CAX (Cortexin) CAX works synergistically with Selank to address mood disorders across the full spectrum — both the anxious and depressive dimensions. Where Selank is particularly strong on anxiety, CAX adds the mood-lifting and motivational component. Supports neuronal metabolism, reduces excitotoxicity, and has demonstrated neuroprotective effects in clinical settings. The Selank + CAX combination addresses both ends of the anxiety-depression spectrum more completely than either compound alone.
-
Sleep foundation — always indicated Epithalon Poor sleep is both a symptom and a driver of anxiety and depression. Epithalon restores deep sleep architecture through pineal gland support — creating the overnight recovery environment that mood regulation depends on. Also normalizes the growth hormone pulse that supports neuronal repair during sleep. Considered foundational in any mood-focused peptide protocol.
-
Mitochondrial energy support SS-31 (Elamipretide) Targets the inner mitochondrial membrane to reduce oxidative stress and improve ATP production at the neuronal level. Directly supports the metabolic foundation that Dr. Palmer's framework identifies as central to mood disorder recovery. Available as subcutaneous injection or nasal spray.
-
Gut-brain axis & inflammation BPC-157 The gut-brain axis is increasingly recognized as central to mood regulation — with gut inflammation directly affecting serotonin production and neuroinflammation. BPC-157 repairs gut lining integrity, reduces systemic inflammation, and works along the vagus nerve — the primary gut-brain communication pathway. Particularly relevant for mood disorders with a significant inflammatory component.
Combining peptides with psychiatric medications requires physician oversight. People currently taking SSRIs, SNRIs, MAOIs, antipsychotics, or mood stabilizers should not add peptide therapy without consulting their prescribing physician. Some peptide interactions — particularly with serotonergic medications — require careful management. This is not a barrier to exploration — but it requires proper supervision.
The Mood Protocol Stack
Each compound addresses a different layer of the mood disorder cascade.
Selank as the primary anchor — with Epithalon for sleep restoration. Add SS-31 if cognitive fog and fatigue accompany the anxiety. BPC-157 if gut symptoms or systemic inflammation are present.
CAX as the primary anchor — with Selank added for the neuroplasticity and cognitive clarity benefits. Epithalon always included for sleep. SS-31 for the mitochondrial energy foundation.
Selank + CAX together as the full anchor combination. This is the most common clinical presentation and the combination both compounds were designed to address together.
Selank and CAX effects on anxiety and mood often taper over 4–8 weeks post-course. Cycling protocols of 2–4 courses per year are commonly used for maintenance. Your provider should design a protocol matched to your response pattern.
Frequently Asked Questions
This requires physician oversight — particularly for SSRIs and SNRIs. Selank and CAX have low interaction risk with most antidepressants, but any change to a psychiatric medication regimen should be discussed with your prescribing physician. Some practitioners use peptides as a bridge during antidepressant tapering under close supervision.
Many people notice anxiety reduction from Sela nk within the first few days of a course. CAX's mood-lifting effects typically develop more gradually over 2–4 weeks. Sleep improvements from Epithalon are often the earliest and most noticeable change — with mood benefits following as sleep quality improves.
People with a history of bipolar disorder, psychosis, or other serious psychiatric conditions should approach peptide therapy with heightened caution and must have close physician oversight. Some interventions that improve energy and mood can theoretically shift mood states in ways that need monitoring. This is not a barrier to exploring peptide therapy — but it requires a provider who understands your full psychiatric history.
No. Peptide therapy works best as part of a comprehensive approach that includes appropriate psychotherapy, lifestyle foundations (sleep, exercise, nutrition), and medical supervision. It addresses the metabolic and neurological substrate that makes mood regulation possible — not the psychological and relational dimensions that therapy addresses. The most effective outcomes combine both.
Depression Peptide Guide
This guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Peptide therapy is not FDA-approved for anxiety or depression. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol — especially if you are currently taking psychiatric medications. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.